{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:21:03Z","timestamp":1790997663725,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jpba.2024.116627","type":"journal-article","created":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T01:32:03Z","timestamp":1733621523000},"page":"116627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Quantification of serum daratumumab in multiple myeloma patients by LC-MS\/MS, comparison with ELISA"],"prefix":"10.1016","volume":"255","author":[{"given":"Weiqiang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoran","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2024.116627_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.624661","article-title":"Daratumumab for the management of newly diagnosed and relapsed\/refractory multiple myeloma: current and emerging treatments","volume":"10","author":"Offidani","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jpba.2024.116627_bib2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/10428194.2018.1485914","article-title":"Daratumumab for the treatment of AL amyloidosis","volume":"60","author":"Sidiqi","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.jpba.2024.116627_bib3","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/14712598.2017.1322578","article-title":"Daratumumab for the treatment of multiple myeloma","volume":"17","author":"Touzeau","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.jpba.2024.116627_bib4","first-page":"551","article-title":"Daratumumab: monoclonal antibody therapy to treat multiple myeloma","volume":"52","author":"Xia","year":"2016","journal-title":"Drug\u00a0Today"},{"key":"10.1016\/j.jpba.2024.116627_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.tmrv.2021.06.002","article-title":"Daratumumab: beyond multiple myeloma","volume":"35","author":"Ejaz","year":"2021","journal-title":"Transfus. Med. Rev."},{"key":"10.1016\/j.jpba.2024.116627_bib6","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1309\/74R4TB90BUWH27JX","article-title":"Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma","volume":"121","author":"Lin","year":"2004","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.jpba.2024.116627_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.597959","article-title":"CD38: an immunomodulatory molecule in inflammation and autoimmunity","volume":"11","author":"Piedra-Quintero","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jpba.2024.116627_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.jpba.2024.116627_bib9","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.jpba.2024.116627_bib10","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2024.116627_bib11","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2024.116627_bib12","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2024.116627_bib13","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2024.116627_bib14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s40262-023-01240-8","article-title":"Clinical pharmacokinetics and pharmacodynamics of daratumumab","volume":"62","author":"Kim","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2024.116627_bib15","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40262-016-0477-1","article-title":"Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment","volume":"56","author":"Clemens","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2024.116627_bib16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jim.2018.12.005","article-title":"Measurement of IL-21 in human serum and plasma using ultrasensitive MSD S-PLEX\u00ae and Quanterix SiMoA methodologies","volume":"466","author":"Poorbaugh","year":"2019","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jpba.2024.116627_bib17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4155\/bio-2018-0240","article-title":"Direct quantitation of therapeutic antibodies for pharmacokinetic studies using immuno-purification and intact mass analysis","volume":"11","author":"Vasicek","year":"2019","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2024.116627_bib18","doi-asserted-by":"crossref","DOI":"10.1039\/D4AY00404C","article-title":"Quantitative assessment of daratumumab in serum via intact light chain measurement using liquid chromatography-high resolution mass spectrometry: a method suitable for therapeutic drug monitoring","author":"Canil","year":"2024","journal-title":"Anal. Methods"},{"key":"10.1016\/j.jpba.2024.116627_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2019.112991","article-title":"Bioanalytical methods for therapeutic monoclonal antibodies and antibody\u2013drug conjugates: a review of recent advances and future perspectives","volume":"179","author":"Todoroki","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116627_bib20","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.4155\/bio-2020-0204","article-title":"Bottom-up sample preparation for the LC\u2013MS\/MS quantification of anti-cancer monoclonal antibodies in bio matrices","volume":"12","author":"de Jong","year":"2020","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2024.116627_bib21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jchromb.2019.01.032","article-title":"Intact protein bioanalysis by liquid chromatography High-resolution mass spectrometry","volume":"1110","author":"Bults","year":"2019","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2024.116627_bib22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s10637-023-01392-1","article-title":"Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma","volume":"41","author":"Yamaoka","year":"2023","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.jpba.2024.116627_bib23","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jpha.2022.08.003","article-title":"LC-MS\/MS method for the quantitation of serum tocilizumab in rheumatoid arthritis patients using rapid tryptic digestion without IgG purification","volume":"12","author":"Mochizuki","year":"2022","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2024.116627_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2023.123991","article-title":"A robust and validated LC\u2013MS\/MS method for the quantification of ramucirumab in rat and human serum using direct enzymatic digestion without immunoassay","volume":"1234","author":"Huang","year":"2024","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2024.116627_bib25","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.jproteome.7b00890","article-title":"Development of a targeted mass-spectrometry serum assay to quantify M-protein in the presence of therapeutic monoclonal antibodies","volume":"17","author":"Zajec","year":"2018","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.jpba.2024.116627_bib26","first-page":"431","article-title":"Comparison of several regression procedures for method comparison studies and determination of sample sizes.2. Application of linear-regression procedures for method comparison studies in clinical-chemistry","volume":"22","author":"Passing","year":"1984","journal-title":"J. Clin. Chem. Clin. Biochem."},{"key":"10.1016\/j.jpba.2024.116627_bib27","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(86)91008-1","article-title":"Regression-analysis","volume":"1","author":"Bland","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2024.116627_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115188","article-title":"Development and validation of a LC\u2013MS\/MS method for quantitation of recombinant human growth hormone in rat plasma and application to a pharmacokinetic study","volume":"224","author":"Huang","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116627_bib29","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40262-016-0477-1","article-title":"Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment","volume":"56","author":"Clemens","year":"2017","journal-title":"Clin. Pharmacokinet."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524006691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524006691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:18:43Z","timestamp":1769689123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524006691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":29,"alternative-id":["S0731708524006691"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116627","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantification of serum daratumumab in multiple myeloma patients by LC-MS\/MS, comparison with ELISA","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116627","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116627"}}